New drug combo tested to keep aggressive lung cancer at bay
NCT ID NCT07110103
Summary
This study is testing whether adding a new drug called golidocitinib to standard immunotherapy (PD-1 inhibitors) can help control extensive-stage small cell lung cancer for longer. After initial chemotherapy, participants receive the two-drug combination as maintenance therapy to try to delay cancer progression. The main goal is to see if this approach is safe and effective at keeping the cancer from worsening.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xinqiao Hospital, Third Military Medical University
RECRUITINGChongqing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.